



May 11, 2022

Donor Selection Criteria for Inclusion in the UCSD Female Reproductive TMC

Valentina Stanley¹, Mana Parast¹, Louise Laurent¹¹University of California, San Diego

1

dx.doi.org/10.17504/protocols.io.b49tqz6n

Human BioMolecular Atlas Program (HuBMAP) Method Development Community
Tech. support email: Jeff.spraggins@vanderbilt.edu

Valentina Stanley
University of California, San Diego

This document outlines the inclusion and exclusion criteria for donors of placenta, fallopian tubes and uterine myometrium in the Human BioMolecular Atlas Program (HuBMAP).

DOI

dx.doi.org/10.17504/protocols.io.b49tqz6n

Valentina Stanley, Mana Parast, Louise Laurent 2022. Donor Selection Criteria for Inclusion in the UCSD Female Reproductive TMC. **protocols.io**
<https://dx.doi.org/10.17504/protocols.io.b49tqz6n>

HuBMAP, UCSD Female Reproductive TMC



document ,

Feb 17, 2022

May 11, 2022

58387

This document outlines the inclusion and exclusion criteria for donors of placenta, fallopian tubes and uterine myometrium in the Human BioMolecular Atlas Program (HuBMAP).

HuBMAP Donor Selection Criteria for Inclusion in the UCSD Female Reproductive TMC

INCLUSION CRITERIA

- Healthy pregnant women without maternal comorbidities or current pregnancy complications or previous history of poor obstetrical outcome
- Patients 18 years or older
- Patients planning to deliver at a UCSD Medical Center

EXCLUSION CRITERIA

- Patients under the age of 18 years
- Patients with Tuberculosis (TB), HIV, Hepatitis B or Hepatitis C
- Patients currently institutionalized for a psychiatric disorder, have intellectual disability or who are currently incarcerated
- Patients with abnormal serum analytes, as defined by one or more of the following: Low PAPP-A (<0.30), High AFP (>2.5), High HCG (>3.0), High Inhibin (>2.0), Low UE3 (<0.30)
- Patients with poor pregnancy outcome as defined by severe preeclampsia, placental abruption, PPRM, short cervix, eclampsia, HELLP syndrome, intrauterine growth restriction (newborn < 5th percentile for gestational age), or stillbirth (>16 weeks' gestation), or intrauterine fetal death with placental involvement
- Patients with maternal medical comorbidities as defined by having any of the following: gestational hypertension, renal disease, Type 1 or Type 2 diabetes, antiphospholipid antibody syndrome, lupus, or other autoimmune disorders
- Patients with any other fetal complication including, but not restricted to, fetal structural anomalies or genetic abnormalities
- Any other pregnancy or maternal complication including, but not restricted to, structural placental membrane or cord abnormalities, multifetal gestation, placenta accreta spectrum, etc.